EPIDYOLEX

This brand name is authorized in Austria, Australia, Estonia, Finland, France, Croatia, Ireland, Italy, Lithuania, Poland, Romania, United Kingdom

Active ingredients

The drug EPIDYOLEX contains one active pharmaceutical ingredient (API):

1 Cannabidiol UNII 19GBJ60SN5 - CANNABIDIOL

Cannabidiol is indicated for the treatment of seizures associated with Lennox‑Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older. Read about Cannabidiol

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
EPIDYOLEX Oral solution	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N03AX24		N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AX Other antiepileptics
Discover more medicines within N03AX24

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 12467E
Country: EE	Ravimiamet	Identifier(s): 1801460, 1849866
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 400959
Country: FR	Base de données publique des médicaments	Identifier(s): 61680130
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 380299
Country: IE	Health Products Regulatory Authority	Identifier(s): 89117
Country: IT	Agenzia del Farmaco	Identifier(s): 048251019
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1088498
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100417524
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69656001